IGM Biosciences Inc. (NASDAQ:IGMS) shares traded -1.23% lower at $25.70 on Wall Street last session.
IGMS stock price is now 25.74% away from the 50-day moving average and 36.45% away from the 200-day moving average. The market capitalization of the company currently stands at $907.72M.
On October 17, 2022, JP Morgan recently initiated its ‘Neutral’ rating on the stock quoting a target price of $27, while ‘BofA Securities’ rates the stock as ‘Buy’.
In other news, BEHRENS M KATHLEEN, Director bought 60,000 shares of the company’s stock on Nov 08. The stock was bought for $1,028,550 at an average price of $17.14. Upon completion of the transaction, the Director now directly owns 218,200 shares in the company, valued at $5.61 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Oct 04, Chief Scientific Officer Keyt Bruce sold 25,000 shares of the business’s stock. A total of $570,980 was realized by selling the stock at an average price of $22.84. This leaves the insider owning 39,489 shares of the company worth $1.01 million. Insiders disposed of 93,257 shares of company stock worth roughly $2.4 million over the past 1 year. A total of 1.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in IGMS stock. A new stake in IGM Biosciences Inc. shares was purchased by T. ROWE PRICE INVESTMENT MANAGEMENT, INC. during the first quarter worth $15,077,000. CANDRIAM S.C.A. invested $1,253,000 in shares of IGMS during the first quarter. In the first quarter, EXODUSPOINT CAPITAL MANAGEMENT, LP acquired a new stake in IGM Biosciences Inc. valued at approximately $655,000. INDEXIQ ADVISORS LLC acquired a new stake in IGMS for approximately $359,000. BNP PARIBAS ARBITRAGE, SNC purchased a new stake in IGMS valued at around $299,000 in the second quarter.
IGM Biosciences Inc. (NASDAQ: IGMS) opened at $25.47 on Wednesday. During the past 12 months, IGM Biosciences Inc. has had a low of $12.67 and a high of $61.97. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 10.80, and a quick ratio of 10.80.